title: A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
abstract: To understand differences in patient reported outcomes (PRO) between patients initiating mirabegron or an antimuscarinic using a validated PRO instrument, OAB-Satisfaction (OAB-S).
  
  
  
  This prospective observational study used real-time prescription claims from Humana to identify Medicare patients initiating mirabegron or an antimuscarinic to participate in a series of three phone surveys over ninety days.
  
  
  
  A total of 1897 mirabegron and 2444 randomly selected antimuscarinic initiators were identified; 174 mirabegron and 193 antimuscarinic initiators completed all three surveys. Among responders, mirabegron initiators were slightly older (76 vs 75 years, P = 0.032), included more males (32% vs 23%, P = 0.044), more likely to have prior OAB treatment (21% vs 13%, P = 0.048), and had greater medication burden (number of unique medications: 10.0 vs 8.7, P = 0.014). There were no between-group differences at any time or on any OAB-S scale. There were significant within-group differences at follow-up compared to baseline for OAB-S scales: "impact on daily living," with improvement over the 90-day survey period for both mirabegron (P = 0.008) and antimuscarinic (P < 0.001); "interruption of day-to-day life," with improvement for both mirabegron (P < 0.001) and antimuscarinic (P < 0.001); and improvement in "OAB control" for mirabegron (P < 0.001) and antimuscarinic (P < 0.001).
  
  
  
  Mirabegron initiators tended to be older, had a greater number of unique medications and previously tried prescriptions to treat OAB; nonetheless, mirabegron, and antimuscarinic initiators reported similar trends in improvement in PROs over the first 90 days of treatment. Significant improvement in daily impact of OAB was observed after treatment initiation; however, no significant differences between groups were observed.
authors.affiliation: Comprehensive Health Insights, Humana, Louisville, Kentucky.
authors.forename: Suvapun
authors.identifier: 0000-0002-1778-6762
authors.initials: S
authors.lastname: Bunniran
authors.affiliation: Comprehensive Health Insights, Humana, Louisville, Kentucky.
authors.forename: Cralen
authors.initials: C
authors.lastname: Davis
authors.affiliation: Astellas Pharma Global Development, Inc., Northbrook, Illinois.
authors.forename: Rita
authors.initials: R
authors.lastname: Kristy
authors.affiliation: Astellas Pharma Global Development, Inc., Northbrook, Illinois.
authors.forename: Daniel
authors.initials: D
authors.lastname: Ng
authors.affiliation: Astellas Pharma Global Development, Inc., Northbrook, Illinois.
authors.forename: Carol R
authors.initials: CR
authors.lastname: Schermer
authors.affiliation: Comprehensive Health Insights, Humana, Louisville, Kentucky.
authors.forename: Claudia
authors.initials: C
authors.lastname: Uribe
authors.affiliation: Comprehensive Health Insights, Humana, Louisville, Kentucky.
authors.forename: Brandon T
authors.initials: BT
authors.lastname: Suehs
mesh_terms: D000083:Acetanilides / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D000071066:Patient Reported Outcome Measures; D017060:Patient Satisfaction; D011446:Prospective Studies; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D064804:Urological Agents / Q000627:therapeutic use*
chemical_list: D000083:Acetanilides; D018727:Muscarinic Antagonists; D013844:Thiazoles; D064804:Urological Agents; C520025:mirabegron
keywords: OAB-S; PRO; mirabegron; overactive bladder; patient reported outcomes